News of Note—Heartflow's noninvasive CAD test gets coverage in California, Alabama

Here's Friday's medtech news of note.

> Anthem Blue Cross Blue Shield, Blue Shield of California, and Blue Cross and Blue Shield of Alabama have issued a positive medical policy for Heartflow’s noninvasive coronary artery disease test, the Heartflow FFRct Analysis, which uses CT images to create a 3D model of a patient’s coronary arteries. Release

> Thermo Fisher set up a consortium in Europe to push the adoption of next-generation sequencing clinical research panels to help identify biomarkers associated with cancer immunotherapy. Release

> Hologic is rolling out its Brevera breast biopsy system, the first to combine tissue acquisition, real-time imaging, sample verification and advanced postbiopsy handling in one system. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Baxter teams up with healthcare incubator Matter on products and technology based on patient-driven innovation. Release

> Abbott won reimbursement for its FreeStyle Libre glucose-monitoring system in Japan. Release

Suggested Articles

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

A new $100 million (€85 million) capital fund out of Germany has closed and is looking for “ground-breaking” heart disease tech.